Caring Brands, Inc.

What they do

Caring Brands develops and markets over-the-counter (OTC) and cosmetic wellness products, including hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products. Its flagship product, Photocil, is a narrow-band UV filter (around 311nm) marketed as a cosmetic in India for vitiligo and psoriasis, with a planned U.S. relaunch targeted for 2026. The company has nominal revenue, primarily from past product sales.

Revenue drivers

• Photocil (India) — Commercial launch in India for vitiligo and psoriasis since Q3 2022; generates minimal revenue (recent six-month 2025 revenue was $3,056).
• Photocil (U.S.) — Briefly launched December 2022–February 2023, removed due to insufficient sales; no current U.S. revenue, targeted relaunch in 2026.
• Other pipeline products — Hair loss, eczema, psoriasis, vitiligo, suncare, and women's sexual wellness products are in development; no current revenue contribution.

Recent performance

For the six months ended June 30, 2026, the company reported zero revenue (down from $3,056 in the year-ago period) and a net loss of $2.6 million, with a net loss attributable to common stockholders of $4.8 million after preferred stock accretion and dividends. For the full year 2025, annual revenue was $4,215, with a net loss of $6.3 million (diluted EPS -$0.46) and operating cash flow of -$1.7 million. As of June 30, 2026, cash was $1.8 million, total assets $1.9 million, total liabilities $384,646, and shareholder equity was negative $2.7 million.

Strategy

Management is preparing for a U.S. relaunch of Photocil in 2026, exploring manufacturing and marketing options, with the formulation unchanged. The company also continues to develop its product pipeline across multiple wellness categories, following a method of operation requiring established mechanisms, controlled clinical trials, patents, and commercial stability. Recent financing activities include issuing Series A Convertible Redeemable preferred stock (4,233 shares outstanding as of June 30, 2026) to raise capital, and the company has received delisting notices from its exchange, indicating a focus on compliance and capital raising.

Risks

• Limited operating history — The company is a newly established business with a limited track record, making it difficult to evaluate prospects and increasing the risk of failure.
• Nominal revenue and recurring losses — Annual revenue of $4,215 in 2025 and net losses of $6.3 million, with negative shareholder equity, indicate the company is not yet commercially viable.
• Photocil U.S. market failure — The product was removed from the U.S. market in early 2023 due to insufficient sales, and a relaunch may face similar challenges without a dedicated sales team.
• Delisting risk — The company received delisting notices in April 2026 and July 2026, which could lead to loss of public market listing and liquidity.

Outlook

Management expects to relaunch Photocil in the U.S. market in 2026, though no specific timeline or milestones are provided beyond the target year. The company continues to develop its pipeline, but forward-looking statements caution that growth in phototherapy and market acceptance is uncertain. The company has not provided formal revenue or profitability guidance.